ORY — ORYZON Genomics SA Share Price
Last trade - 00:00- €117.76m
- €119.19m
- 22
- 32
- 40
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.44 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.03% | ||
| Return on Equity | -4.34% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | 2.15 | 6.73 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
Directors
- Carlos Manuel Buesa Arjol CHM
- Tamara Maes VCH
- Enric Rello CFO
- Torsten Hoffmann CSO (53)
- Michael Ropacki VPR
- Jordi Xaus VPR
- Emili Torrell VBD
- Roger Bullock OTH (69)
- Sonia Gutierrez OTH
- Neus Virgili OTH
- Manuel Lopez-Figueroa LED
- Josep Maria Echarri Torres DRC
- Ramon Adell Ramon IND (63)
- Isabel Aguilera Navarro IND (61)
- Antonio Fornieles Melero IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 1st, 1970
- Public Since
- December 10th, 2015
- No. of Employees
- 44
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Madrid Stock Exchange
- Shares in Issue
- 62,173,519
- Address
- Sant Ferran 74, CORNELLA DE LLOBREGAT, 08940
- Web
- http://www.oryzon.com/
- Phone
- +34 935151313
- Auditors
- Deloitte SL
Latest News for ORY
Upcoming Events for ORY
Q1 2024 Oryzon Genomics SA Earnings Release
Oryzon Genomics SA Annual Shareholders Meeting
Q2 2024 Oryzon Genomics SA Earnings Release
Q3 2024 Oryzon Genomics SA Earnings Release
Similar to ORY
Biotechnology Assets SA
Madrid Stock Exchange
Pangaea Oncology SA
Madrid Stock Exchange
FAQ
As of Today at 19:16 UTC, shares in ORYZON Genomics SA are trading at €1.89. This share price information is delayed by 15 minutes.
Shares in ORYZON Genomics SA last closed at €1.89 and the price had moved by -11.5% over the past 365 days. In terms of relative price strength the ORYZON Genomics SA share price has underperformed the FTSE Global All Cap Index by -16.91% over the past year.
The overall consensus recommendation for ORYZON Genomics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ORYZON Genomics SA does not currently pay a dividend.
ORYZON Genomics SA does not currently pay a dividend.
ORYZON Genomics SA does not currently pay a dividend.
To buy shares in ORYZON Genomics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €1.89, shares in ORYZON Genomics SA had a market capitalisation of €117.76m.
Here are the trading details for ORYZON Genomics SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: ORY
Based on an overall assessment of its quality, value and momentum ORYZON Genomics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ORYZON Genomics SA is €6.40. That is 237.91% above the last closing price of €1.89.
Analysts covering ORYZON Genomics SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.10 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ORYZON Genomics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -18.24%.
As of the last closing price of €1.89, shares in ORYZON Genomics SA were trading -4.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ORYZON Genomics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.89.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ORYZON Genomics SA's management team is headed by:
- Carlos Manuel Buesa Arjol - CHM
- Tamara Maes - VCH
- Enric Rello - CFO
- Torsten Hoffmann - CSO
- Michael Ropacki - VPR
- Jordi Xaus - VPR
- Emili Torrell - VBD
- Roger Bullock - OTH
- Sonia Gutierrez - OTH
- Neus Virgili - OTH
- Manuel Lopez-Figueroa - LED
- Josep Maria Echarri Torres - DRC
- Ramon Adell Ramon - IND
- Isabel Aguilera Navarro - IND
- Antonio Fornieles Melero - IND